Novartis rethinks sales strategy for new cholesterol drug launch
Swiss drugmaker hopes to unlock large but tricky heart-medicine market with broad rollouts via hospital systems22-11-2021
22-11-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificate to the shareholder as detailed in the attachment, as per the information received from the Company's Registrar and Share Transfer Agent on November 15, 2021. Request you to take the same on record.16-11-2021
Novartis India Ltd - 500672 - Intimation Of Newspaper Advertisement By Novartis India Limited ('The Company') Regarding The Unaudited Financial Results Of The Company For The Second Quarter Ended September 30, 2021
Dear Sirs, Apropos the subject matter quoted above, please find enclosed herewith the copies of the newspaper Notices in 'Financial Express' and 'Navshakti' on November 12, 2021. This is for your information and record.12-11-2021
Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Dear Sir/ Madam, Pursuant to Regulation 30 of SEBI LODR Regulations, we would like to inform you that Mr. Trivikram Guda has tendered his resignation from the position of the Company Secretary and Compliance Officer of the Company, to pursue opportunities outside of Novartis. The resignation is accepted and he will be relieved from his responsibilities at the end of business hours on November 30, 2021. The Company is in the process of identifying a suitable successor and the same will be communicated to the stock exchange, once the position is filled up. Kindly take note of the above on record.11-11-2021
Novartis India Ltd - 500672 - Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2021
Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, November 11, 2021 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2021. In terms of the applicable provisions of SEBI LODR Regulations, please find enclosed herewith: a. the Unaudited Financial Results; and b. Limited Review Report dated November 11, 2021, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company, as Annexure 1. The said meeting commenced at 11:30 a.m. and concluded at 3:00 p.m. Kindly take note of the above on record.11-11-2021
Novartis India Ltd - 500672 - Board Meeting Outcome for 1. Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited ('The Company') Held On November 11, 2021 2. Resignation Of Company Secretary And Compliance Officer Of The Company
Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, November 11, 2021 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2021. Further, pursuant to Regulation 30 of SEBI LODR Regulations, we would like to inform you that Mr. Trivikram Guda has tendered his resignation from the position of the Company Secretary and Compliance Officer of the Company, to pursue opportunities outside of Novartis. The resignation is accepted and he will be relieved from his responsibilities at the end of business hours on November 30, 2021. The Company is in the process of identifying a suitable successor and the same will be communicated to the stock exchange, once the position is filled up. The said meeting commenced at 11:30 a.m. and concluded at 3:00 p.m.11-11-2021
Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale
The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring04-11-2021
Novartis weighs sale or spinoff of generic drug unit Sandoz
Swiss drug giant's review of generics business comes as it grapples with falling prices for copy-cat medicines26-10-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholder has lost his share certificate, as per the information received from the Company's Registrar and Share Transfer Agent on October 22, 2021 as detailed in the attachment.22-10-2021
Novartis signs new deal to help produce Pfizer/BioNTech vaccine
Novartis has been using its factory in Stein in Switzerland to produce more than 50 million doses this year of the mRNA Covid-19 vaccine developed by German startup BioNTech and US drugmaker Pfizer.21-10-2021